Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Unlock Full EXAS Analysis
UpgradeKey Numbers
Market Cap
$14B
P/E
N/A
Revenue Growth
+15.0%
Gross Margin
N/A
ROE
N/A
About Exact Sciences
Listed on the NASDAQ, Exact Sciences operates as a mid-cap player in the healthcare sector, offering investors focused access to biotech and genomics growth drivers. Cancer screening pioneer with Cologuard and liquid biopsy development. With a $14B market capitalization and no current profitability, the business is characterized by consistent top-line gains, reporting +15% revenue change year-over-year.
Expert Coverage
Loading coverage...
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-03-22
More in Biotech & Genomics
ARKG
ARK Genomic Revolution ETF
89
True North
Mixed
ETF focused on companies advancing genomics, gene editing, and therapeutics.
CBOE
MCap $2BDXCM
DexCom Inc.
85
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55ALNY
Alnylam Pharmaceuticals
85
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%LLY
Eli Lilly and Company
85
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65